首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >The Therapeutic Effects of a Traditional Chinese Medicine Formula Wuzi Yanzong Pill for the Treatment of Oligoasthenozoospermia: A Meta-Analysis of Randomized Controlled Trials
【24h】

The Therapeutic Effects of a Traditional Chinese Medicine Formula Wuzi Yanzong Pill for the Treatment of Oligoasthenozoospermia: A Meta-Analysis of Randomized Controlled Trials

机译:中药式武子燕宗丸治疗寡孢素孢子症的治疗效果:随机对照试验的荟萃分析

获取原文
           

摘要

Oligoasthenozoospermia is a crucial factor in male infertility. Wuzi Yanzong (WZYZ) pill is a popular traditional Chinese medicine (TCM) formula which has been used for male infertility treatment for years. However, its effects on semen quality remain controversial. We conducted a preregistered meta-analysis to assess the effect of WZYZ pill for the therapeutic effects on oligoasthenozoospermia. Five randomized controlled trials including 960 participants were selected from databases of domains in North-East Asian regions, PubMed, Embase, and Cochrane Library. WZYZ pill group yielded a greater mean increment on sperm concentration (5 trials MD 5.99, 95% CI 2.12–9.85, ), sperm motility (5 trials MD 4.57, 95% CI 0.47–8.68, ), sperm morphology (2 trials MD ?1.93, 95% CI ?4.87–1.01, ), activity of acrosomal enzyme (2 trials MD 28.27, 95% CI 12.41–44.14, ), volume of semen (2 trials MD 0.56, 95% CI 0.21–0.91, ), and a decrement of sperm DNA fragmentation index (2 trials MD ?3.82, 95% CI ?6.45–?1.19, ). However, qualities of selected studies were generally unsatisfactory, and there was inherent heterogeneity among some of the outcomes. Despite these limitations, the WZYZ pill improved sperm quality by improving several semen parameters and decreasing DNA damage in oligoasthenozoospermia patients.
机译:寡血管生成血症是男性不孕症的关键因素。武子燕宗(WZYZ)丸是一种受欢迎的中药(TCM)配方,已被用于男性不孕症治疗多年。然而,它对精液质量的影响仍然存在争议。我们进行了预期的荟萃分析,以评估WZYZ丸对寡孢菌菌治疗作用的影响。包括960名参与者的五项随机对照试验,选自东北亚洲地区,博彩,EMBASE和Cochrane图书馆的域的数据库。韦兹药丸组对精子浓度产生更大的平均值(5试验MD 5.99,95%CI 2.12-9.85,),精子运动(5试验MD 4.57,95%CI 0.47-8.68,),精子形态(2试验MD? 1.93,95%CIα.4.87-1.01,),吸解素酶活性(2试验MD 28.27,95%CI 12.41-44.14,),精液体积(2试验MD 0.56,95%CI 0.21-0.91,),和精子DNA碎片指数的递减(2试验MD?3.82,95%CI?6.45-?1.19)。然而,所选研究的质量通常不令人满意,其中一些结果中存在固有的异质性。尽管有这些局限性,WZYZ丸通过改善几种精液参数和降低寡核苷酸患者的DNA损伤而改善精子质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号